Skip to main content
OpenTrials
Completed

NCT Number: NCT01492712

Validation Study of Covariates Model (VaSCoM) for Propofol

Anaesthesia for surgical procedures can be provided using a continuous infusion of intravenous drug. The most commonly used drug for this technique is propofol. Infusion devices programmed with pharmacokinetic models can be used to infuse propofol to achieve a target blood concentration. These pharmacokinetic models predict the rate of distribution of propofol within the body and also the rate at which it is cleared. In practice, the anaesthetist enters patient details such as age, sex and weight as well as a target blood concentration of propofol. The infusion device then infuses propofol at the appropriate rate to achieve this concentration.

White and colleagues recently published the Covariates Model for propofol. It is anticipated that this model will have reduced bias and inaccuracy compared to the models in current clinical use. The VaSCoM study has three objectives:

1. Prospective validation of the Covariates Model 2. Modelling of the effect site concentration of propofol 3. Comparison of propofol concentration in venous and arterial blood samples

To achieve the above objectives, patients over 18 years of age and undergoing elective non-cardiac surgery will be recruited to the study. Anaesthesia will be delivered using a target controlled infusion device programmed with the Covariates Model for propofol. The target blood concentrations will be set according to a pre-determined schedule and all measurements will be made prior to the start of surgery.

Prospective validation of the Covariates Model will be done by comparing blood concentration of propofol predicted by the model to those actually measured. These results will then be compared to the predictions made using the models in current clinical practice.

Modelling of the effect site means predicting the concentration of propofol in the brain for a given blood concentration. This will involve using depth of anaesthesia monitors (such as bispectral index) as surrogate markers of brain concentration and comparing this to the predicted and measured blood concentrations of propofol.

Finally, important information on the distribution and clearance of propofol can be gained through the comparison of venous and arterial blood samples. In this study, simultaneous sampling of venous and arterial blood will facilitate this comparison.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Golden Jubilee National Hospital

Clydebank, G81 4HX, United Kingdom

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged over 18 years
  • ASA I/II
  • Elective non-cardiac surgery expected to last longer than 30 minutes

Exclusion criteria

  • Patient refusal or unable to consent
  • Premedication, sedative or anaesthetic in the previous 12 hours
  • Pre-operative GCS less than 15
  • ASA III/IV
  • Allergy to constituents of propofol
  • Excess alcohol intake
  • Drug abuse
  • Mental retardation
  • Difficult airway
  • BMI over 35

Treatment and study plan

Propofol

Drug

Patients in the low-high-low group will receive an infusion of propofol with an initial blood target concentration of 2 mcg/ml. After 15 minutes the target will be increased to 5 mcg/ml and after a further 15 minutes the target will be reduced back to 2 mcg/ml for a further 15 to 30 minutes.

Primary outcomes

  1. Performance error of predicted blood propofol concentration (venous blood samples)

    Time frame: 1.5, 5, 16.5, 20, 31.5, 35, 45-60 minutes post infusion start time

    Performance error is calculated as:

    ((Measured blood concentration - Predicted blood concentration)/ Predicted blood concentration) x 100

    The median performance error and the absolute performance error can then be calculated as measures of bias and inaccuracy respectively.

Secondary outcomes

  1. Depth of anaesthesia

    Time frame: 0 to 45-60 minutes post infusion start time

    Depth of anaesthesia (as measured by bispectral index and index of consciousness) will be used as a surrogate marker of propofol effect site concentration. By using complex statistical analysis to compare depth of anaesthesia to measured and predicted blood concentrations, we aim to determine the Keo. This is the rate constant for elimination of propofol from the effect site compartment and will be incorporated to the Covariates Model to predict brain concentration for a given blood concentration of propofol.

  2. Comparison of performance errors calculated from venous blood samples to performance errors calculated from arterial blood samples

    Time frame: 1.5, 5, 16.5, 20, 31.5, 35, 45-60 minutes post infusion start time

    Performance error is calculated as:

    ((Measured blood concentration - Predicted blood concentration)/ Predicted blood concentration) x 100

Sponsors and collaborators

Lead sponsor

Golden Jubilee National Hospital

Other Gov

Registry information

Acronym: VaSCoM

Important dates

Study start
2011
Primary completion
2013
Study completion
2013
First posted
Dec 15, 2011
Registry last updated
Aug 14, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.